China’s drug regulator has conditionally approved Shanghai Junshi Biosciences Co., Ltd.’s deuremidevir (JT001/VV116) and Simcere Pharmaceutical Group’s combination antiviral simnotrelvir plus ritonavir (SIM0417) as the latest additional home-grown oral antivirals for COVID-19, in a way that reflected the Japanese approval of Shionogi & Co. Ltd.’s Xocova (ensitrelvir).
The regulatory decision, announced by the National Medical Products Administration (NMPA) on 29 January, was based on interim analyses of positive outcomes from two placebo-controlled Phase III trials
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?